Ferric carboxymaltose for anemia in Crohn’s disease patients at a tertiary center: A retrospective observational cohort study

Table 1 Demographic and clinical characteristics of the patients included in the study

Variables	Ferric carboxymaltose	Iron sucrose	P value
Sex (M/F)	12/13	9/7	0.606a
Age (yr)	37 (20-67)	37 (25-67)	0.989b
Disease duration (mo)	144 (6-312)	144 (24-312)	0.718b
Age at the diagnostic A1/A2/A31	1/22/2	1/14/1	0.931a
Disease location L1/L2/L3/L41	5/4/16/0	4/3/9/0	0.882a
Behavior B1/B2/B31	8/13/4	4/8/4	0.750a
Perianal disease (yes/no)	11/14	8/8	0.707a
Prior Surgery (yes/no)	20/05	15/1	0.224a
Biologic therapy (yes/no)	23/2	15/1	0.962a
Immunosuppressive therapy (yes/no)	14/11	13/3	0.242a
Previous blood transfusion (yes/no)	10/15	8/8	0.529a

¹Montreal classification.

^aPearson's χ² test.

^bUnpaired t-test (Mann Whitney) with P < 0.05.

Numerical variables are described in median (minimum and maximum), and the categorical variables in absolute frequency. n = 25. CD: Crohn’s disease; M: Male; F: Female.